Double-masked, placebo-controlled, dose-ranging study of troglitazone 10 to 200 mg once daily in non-insulin-dependent diabetes mellitus

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 7, 1997, Pages 403-416

  Leutenegger, Marc ^a   Sacca, Luigi ^b   Alderton, Claire ^c   Eckland, David ^c   Lettis, Sally ^c  

^a SERVICE DE DERMATOLOGIE   (France)

^b Medicina Interna   (Italy)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Glycemic control; Non insulin dependent diabetes mellitus; Safety; Troglitazone

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; LIPID; PLACEBO; PROINSULIN; TROGLITAZONE;

ADULT; AGED; ARTICLE; BONE PAIN; CAPILLARY BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030862984     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80031-8     Document Type: Article

References (20)

1. Fujiwara T, Yoshioka S, Yoshioka T, et al. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and zucker fatty rats. Diabetes. 1988;37:1549-1558.
2. Fujiwara T, Wada M, Fukuda K, et al. Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism. 1991;40:1213-1218.
3. Horikoshi H, Fujiwara T, Shimada M, et al. Suppression of hepatic gluconeogenesis by CS-045 in KK mice and in perfused liver. Diabetes. 1990;39(Suppl 1):111A. Abstract 442.
4. Ciaraldi T, Huber-Knudsen K, Hickman M, Olefsky JM. Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metabolism. 1995;44:976-982.
5. Inoue Y, Tanigawa K, Nakamura S, et al. Lack of effect of CS-045, a new antidiabetic agent, on insulin secretion in the remnant pancreas after 90% pancreatectomy in rats. Diabetes Res Clin Pract. 1995;27:19-26.
6. Kumar S, Boulton AJM, Beck-Nielsen H, et al, for the Troglitazone Study Group. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia. 1996;39:701-709.
7. Valiquett T, Balagtas C, Whitcomb R. Troglitazone dose response study in patients with NIDDM. Diabetes. 1995;44(Suppl 1):109A. Abstract 406.
8. Norris R, Valiquett T, Balagtas C. Comparison of troglitazone (CI991) dosing regimens and placebo in the treatment of patients with NIDDM. Diabetes. 1993;42(Suppl 1):59A, 187. Abstract.
9. Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992;15:193-203.
10. Iwamoto Y, Kosaka K, Kuzuya T, et al. Effects of troglitazone a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care. 1996;19:151-156.
11. Mimura K, Umeda F, Hiramatsu S, et al. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabetic Med. 1994;11:685-691.
12. Akanuma Y, Kosaka K, Kuzuya T, et al. Clinical evaluation of a new oral hypoglycemic agent CS-045 in patients with non-insulin dependent diabetes mellitus poorly controlled by sulphonylureas - a dose finding study by dose increasing method. J Clin Ther Med. 1993;9(Suppl 3):39-60.
13. Alberti KGMM, Gries FA, Jervell J, Krans HMJ, for the European NIDDM Policy Group. A desktop guide for the management of non-insulin dependent diabetes mellitus (NIDDM): An update. Diabetic Med. 1994;11:899-909.
14. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS) XI: Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabetic Med. 1994;11:534-544.
15. Taskinen MR, Harno K, Nikkila EA. Serum lipids and lipoproteins in type 2 diabetes. Acta Endocrinologia. 1984;262(Suppl):95-99.
16. Kuzuya T, Iwamoto Y, Kosaka K, et al. A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract. 1991;11:147-154.
17. Levin K, Thye-Roenn P, Foot E, Beck-Nielsen H. Metabolic effects of troglitazone in NIDDM patients. Endocrinol Metab. In press.
18. Golay A, Zech L, Shi MZ, et al. High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: Measurement of HDL turnover using tritiated HDL. J Clin Endocrinol Metab. 1987;65:512-518.
19. Cominacini L, Garbin U, Fratta Pasini A, et al. Effect of troglitazone on the susceptibility of LDL to oxidation in healthy volunteers. Diabetologia. 1996;3a(Suppl 1):885. Abstract 233.
20. Groop LC. Sulphonylureas in NIDDM. Diabetes Care. 1992;15:737-754.